Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for treating cataplexy in patients with narcolepsy. The acceptance is a positive regulatory milestone but does not by itself confirm approval or timing.
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for treating cataplexy in patients with narcolepsy. The acceptance is a positive regulatory milestone but does not by itself confirm approval or timing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
